PCSK9 and familial hypercholesterolemia: Although PCSK9 inhibitor antibodies represent a recent avenue of combination treatment with statins and ezetimibe for hypercholesterolemia in patients with treatment-resistant LDL-C levels and/or a history of statin intolerance, their clinical benefits in these patients appear to be very promising.